NO146060B - Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-substituerte-5-alkylresorcinol - Google Patents
Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-substituerte-5-alkylresorcinol Download PDFInfo
- Publication number
- NO146060B NO146060B NO763881A NO763881A NO146060B NO 146060 B NO146060 B NO 146060B NO 763881 A NO763881 A NO 763881A NO 763881 A NO763881 A NO 763881A NO 146060 B NO146060 B NO 146060B
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- octyl
- resorcinol
- diacetyl
- hydroxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 11
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- -1 3-methyl-2-octyl Chemical group 0.000 claims description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 230000000850 deacetylating effect Effects 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- VMCUPNFLRMOSNZ-UHFFFAOYSA-N 5-(3-methyloctan-2-yl)-2-(4-propan-2-ylpyridin-3-yl)benzene-1,3-diol Chemical compound OC1=CC(C(C)C(C)CCCCC)=CC(O)=C1C1=CN=CC=C1C(C)C VMCUPNFLRMOSNZ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229940099340 desoxyn Drugs 0.000 description 4
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 3
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 2
- QVYPBWIVJWFWRW-UHFFFAOYSA-N 1-[5-acetyl-1,5-dihydroxy-3-(3-methyloctan-2-yl)-6-(4-prop-1-en-2-ylpyridin-3-yl)cyclohex-3-en-1-yl]ethanone Chemical compound CC(=O)C1(O)CC(C(C)C(C)CCCCC)=CC(O)(C(C)=O)C1C1=CN=CC=C1C(C)=C QVYPBWIVJWFWRW-UHFFFAOYSA-N 0.000 description 2
- UOLZAOYGJBPQCR-UHFFFAOYSA-N 1-[5-acetyl-1,5-dihydroxy-3-(3-methyloctan-2-yl)-6-(4-propan-2-ylpyridin-3-yl)cyclohex-3-en-1-yl]ethanone Chemical compound CC(=O)C1(O)CC(C(C)C(C)CCCCC)=CC(O)(C(C)=O)C1C1=CN=CC=C1C(C)C UOLZAOYGJBPQCR-UHFFFAOYSA-N 0.000 description 2
- 208000024255 Audiogenic seizures Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- RPOXQWIKCYDBBX-UHFFFAOYSA-N 5-(3-methyloctan-2-yl)-2-(4-prop-1-en-2-ylpyridin-3-yl)benzene-1,3-diol Chemical compound OC1=CC(C(C)C(C)CCCCC)=CC(O)=C1C1=CN=CC=C1C(C)=C RPOXQWIKCYDBBX-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- SONJTKJMTWTJCT-UHFFFAOYSA-K rhodium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Rh+3] SONJTKJMTWTJCT-UHFFFAOYSA-K 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
- C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
- C07C45/66—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups by dehydration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/794—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring
- C07C49/796—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
Analogifremgangsmåte ved fremstilling av terapeutisk aktive 2-substituerte-5-alkyl-. resorcinol.
Description
Foreliggende oppfinnelse vedrører en analogifremgangsmåte ved fremstilling av terapeutisk aktive 2-substituerte-5-alkyl-resorcinoler med formelen
hvor Z = -C(=CH2)CH3 eller -CH (CH-j) 2 og hvor R ' betyr hydro-
gen eller acetyl og R_ betyr 3-metyl-2-oktyl, og X er nitrogen eller C-metyl. J
Fra norsk utlegningsskrift nr. 128.711 er det kjent beslektete forbindelser, men hvor pyridinringen, når X har betydningen nitrogen, er usubstituert. Ytterligere er de beslektede forbindelser i.h.t. nevnte utlegningsskrift 4-pyridylforbindel-
ser, mens, slik som det fremgår av den ovenfor viste formel så er de fremstilte forbindelser 3-pyridylforbindelser når
X har betydningen N.
De foreliggende resorcinoler fremstilles ifølge det følgende reaksjonsskjerna:
Benzopyranonene (I) får reagere med metylmagnesiumbromid i tetrahydrofuran for å danne alkoholene (II) som behandles med eddiksyreanhydrid i pyridin for å gi diacetylderivatene, fulgt av dehydratisering med tionylklorid i pyridin ved -10 til 0°
for å gi isopropenylderivatene (III). Behandling av (III) med flytende ammoniakk i en hoytrykks-bombe ved romtemperatur gir resorcinolene (IV). Hydrogenering av isopropenylderivatene
(III) med 5%'s palladium på karbon i etylacetat gir isopropyl-derivatene (V), som behandles med flytende ammoniakk i en hoytrykks-bombe ved romtemperatur for å gi de deacetylerte deriva-
ter (VI) .
De foreliggende forbindelser som kan fremstilles ifolge det generelle skjema, slik som illustrert og beskrevet foran, om-fatter (vil) l,3-diacetyl-2-[4-isopropylen-3-pyridyl]-5-(3-metyl-2-oktyl)resorcinol :
(X) 2-[4-isopropyl-3-pyridyl]-5-(3-metyl-2-oktyl)resorcinol: (XI) 1,3-diacetyl-2-[(2-isopropenyl-5-metyl)fenyl]-5-(3-metyl-2-oktyl)resorcinol: (XII) 2-[(2-isopropyl-5-metyl)fenyl]-5-(3-metyl-2-oktyl)resorcinol:
Forbindelsene ifolge foreliggende oppfinnelse er anvendelige
som analgetika, beroligende midler, sedative hypnotika og anti-convulsiva. Forbindelsene er effektive ved doser generelt på fra 1 til 10 mg/kg legemesvekt daglig. Den analgetiske aktivitet ble påvist ved standard rottevridningsproven [whittle, Brit, J. Pharmacol., 22, 296 (1964)] og bekreftet ved varm-plate-bestemmelsen [woolfe, G. and McDonald, A. J., J. Pharmacol. Exper. Therap.,
8Q, 300 (1944)] og rottehalebevegelsesproven.
De folgende eksempler illustrerer og beskriver den foreliggende oppfinnelse ytterligere.
EKSEMPEL 1( fremst, av utgangsmateriale)
10-hydroksy-8-(3-metyl-2-oktyl)-5-okso-5H-[lJbenzopyrano-[4,3-c]pyridin
En blanding av 3,42 g 2-benzyl-10-hydroksy-8-(3-metyl-2-oktyl)-5-okso-1,2,3,4-tetrahydro-5H-[ljbenzopyrano[4,3-c]pyridin, 1,0 g 10%'s palladium på karbon og 120 ml xylen ble omrort og tilbakelopsbehandlet i 23 timer. Blandingen ble filtrert for å fjerne katalysatoren og filtratet ble dampet inn til torrhet i vakuum. Resten ble omkrystallisert fra acetonitril for å gi det rene produkt . S.p. 122-123°.
Analyse beregnet for: C21H25N03 : C, 74,31; H 7,42; N, 4,13
funnet: C, 74,08; H 7,36; N, 3,98.
EKSEMPEL 2 (fremst, av utgangsmateriale)
2-/ 1- l(l-hydroksy-l-metyl)etyl]-3-pyridyl7-5-(3-metyl-2-oktyl)-resorcinol
En opplosning av 16,97 g (0,05 mol) 10-hydroksy-8-(3-metyl-2-oktyl)-5-okso-5H-Ll]benzopyrano [_4 , 3-c jpyridin i 125 ml tetrahydrofuran ble gradvis tilsatt til en omrort opplosning av 125 ml 3M metylmagnesiumbromid i eter og 125 ml tetrahydrofuran, slik at opplosningen ble tilbakelopsbehandlet forsiktig. Etter tilsetningen ble reaksjonsblandingen oppvarmet under tilbake-lopskjoling i 1 1/2 time og etter avkjoling ble det spaltet med |-200 ml mettet ammoniumkloridopplosning og ble ekstrahert to ganger med tetrahydrofuran. Tetrahydrofuranekstraktene ble torket over vannfritt natriumsulfat og dampet inn i vakuum for å gi produktet; s.p. 8 2-87° .
EKSEMPEL 3 (fremst, av utgangsmateriale)
1,3-diacetyl-2-/3-[(1-hydroksy-l-metyl)etyl]-3-pyridyl7-5-(3-metyl-2-oktyl)resorcinol
Eddiksyreanhydrid (7,65 g) ble tilsatt dråpevis til en omrort opplosning av 9,73 g 2-/1-[(1-hydroksy-l-metyl)etyl]-3-pyridyl7-5-(3-metyl-2-oktyl)resorcinol i 40 ml torr pyridin, kjolt i et isbad. Blandingen ble omrort ved isbadtemperatur i 1 time og deretter ved romtemperatur over natten og ble konsentrert i vakuum. Resten ble helt i 300 ml isvann og det gummiaktige materiale ble tatt opp i eter. Eteropplosningen ble vasket to ganger med vann, torket over vannfritt natriumsulfat og dampet inn i vakuum for å gi produktet, som ble anvendt for det neste trinn uten ytterligere rensning.
EKSEMPEL 4
1,3-diacetyl-2-[4-isopropenyl-3-pyridyl]-5-(3-metyl-2-oktyl)-resorcinol
Tionylklorid (5 ml) ble tilsatt dråpevis til en omrort opplosning av 1,27 g 1,3-diacetyl-2-/~4-Ll-hydroksy-l-metyl)etyl]-3-pyridyl/-5-(3-metyl-2-oktyl)resorcinol i 40 ml pyridin, kjolt i et is-saltbad ved -10°. iBlandihgen ble omrort og temperaturen fikk stige til 0° i lopet av 1 1/2 time. Blandingen ble helt i isvann og ble ekstrahert med eter. Eterekstraktene ble vasket med vann, torket over vannfritt natriumsulfat og inndampet i vakuum. Resten ble kromatografert på en "Florisil"-kolonne (60-100 mesh) under anvendelse av graderte metanol/benzen-opplos-ningsmiddelblandincer for å gi det rene produkt.
Analyse beregnet for: C27H35N04: C, 74,11; H, 8,06; N, 3,20
funnet C, 74,19; H, 8,02; N, 3,23
EKSEMPEL 5 j
2-[4-isopropenyl-3-pyr idyl]-5-(3-metyl-2-oktyl)resorcinol
En opplosning av 4,37 g 1,3-diacetyl-2-[4-isopropenyl-3-pyri-dyl]-5-(3-metyl-2-oktyl)resorcinol i 50 ml toluen ble anbragt i en hbytrykks-bombe med 40 ml flytende ammoniakk. Blandingen ble rystet ved romtemperatur over natten. Det overskytende ammoniakk fikk unnslippe, resten ble revet med vann og ekstrahert med kloroform. Kloroformekstraktene ble vasket to ganger med vann, torket over vannfritt natriumsulfat og inndampet i vakuum. Resten ble omkrystallisert ifra eter-petroleter (30-60°) for å
gi det rene produkt. S.p. 128-129°.
Analyse beregnet for: C23H31N02: C, 78,14; H, 8,84; N, 3,97
funnet: C, 78,43; H, 8,98; N, 3.99
EKSEMPEL 6
1,3-diacetyl-2-[4-isopropyl-3-pyridyl]-5-(3-metyl-2-oktyl) resorcinol
En opplosning av 6,0 g 1, 3-diaceiyl- 2- [ 4-isopropenyl-3-pyr idyl]-5-( 3-metyl-2-ok.tyl) resorcinol i 200 ml etylacetat med 1, 2 g. 5%'s palladium på karbon ble hydrogenert i et Parr-apparat i 1 1/2 time. Opplosningen ble filtrert og 1,2 g 5%* s palladium på karbon ble tilsatt og blandingen ble hydrogenert i 4 timer. Etter fjerning av katalysatoren ble filtraet inndampet i vakuum for å gi det rene produkt.
Analyse beregnet for: <C>27<H>37N04: C, 73,78; H, 8,52; N, 3,20
funnet: C, 73,47; H, 8,59; N, 3,01
EKSEMPEL 7
2- [4-isopropyl-3-pyridyl]-5-(3-metyl-2-oktyl)resorcinol
2-[4-isopropyl-3-pyridyl]-5-(3-metyl-2-oktyl)resorcinol ble fremstilt ved å behandle 1,3-diacetyl-2-[4-isopropyl-3-pyridyl]-5-(3-metyl-2-oktyl)resorcinol med ammoniakk ifolge fremgangsmåten i eksempel 5. EKSEMPEL 8 (fremst, av'utgangsmateriale) 1-hydroksy-9-metyl-3-(3-metyl-2-oktyl)-6-okso-6H-dibenzo-[b]Id]pyran En blanding av 8,4 g 1-hydroksy-9-metyl-3-(3-metyl-2-oktyl)-6-ok.so-7 ,8 , 9,10-tetrahydro-6H-dibenzo [b] [d]pyran og 2,4 g svovel ble oppvarmet i et oljebad ved 255-260° i 1/2 time. Etter kjb-ling ble 100 ml eter tilsatt til resten og eteropplosningen ble filtrert for å fjerne uopploselig materiale. Filtratet ble konsentrert i vakuum for å gi 7,9 g amorft faststoff. S.p. 80-85°. EKSEMPEL 9 (fremst, av utgangsmateriale) 2-//2-1 (1-hydroksy-l-metyl );etyl ]- 5-metylfeny17-5- ( 3-metyl- 2-oktyl)resorcinol
2-/2- |_ (1-hydroksy-l-metyl)etyl/-5-metylfenyl/- 5- (3-metyl- 2-oktyl)resorcinol ble fremstilt ved omsetning av 1-hydroksy-9-metyl-3-(3-metyl-2-oktyl)-6-okso-6H-dibenzo[b][d]pyran med metylmagnesiumbromid og spalte komplekset med vandig natriumkar-bonat ifolge fremgangsmåten i eksempel 2.
EKSE MPEL 10 (fremst, av utgangsmateriale) 1,3-diacetyl-2-/2-[(1-hydroksy-l-metyl)etyl]-5-metylfenyl7-5-(3-metyl-2-oktyl)resorcinol
1,3-diacetyl-2-/2-[(1-hydroksy-l-metyl)etylJ-5-metylfenyl7-5-(3-metyl-2-oktyl) resorcinol ble fremstilt ved å behandle 2-/"2-[(1-hydroksy-l-metyl)etyl]-5-metylfeny17-5-(3-metyl-2-oktyl)-resorcinol med eddiksyreanhydrid i pyridin ifolge metoden beskrevet i eksempel 3. E KSEMPEL 11 1,3-diacetyl-2-[(2-isopropenyl-5-metyl)fenyl]-5-(3-metyl-2-oktyl)resorcinol 1,3-diacetyl-2-[(2-isopropenyl-5-metyl)fenyl]-5-(3-metyl-2-oktyl)resorcinol ble fremstilt ved omsetning av 1,3-diacetyl-2-/"2- [ (1-hydroksy-l-metyl) etyl]-5-metylf enyl7-5- (3-metyl- 2-oktyl)resorcinol med tionylklorid og pyridin ifolge fremgangsmåten i eksempel 4. Analyse beregnet for: C2gH3g04: C, 77,30; H, 8,50; 0, 14,20 funnet : C, 76,82; H, 8,60; 0, 13,67 EKSEMPEL 12 1,3-diacetyl-2-[(2-isopropyl-5-metyl)fenyl]-5-(3-metyl-2-oktyl)resorcinol
En opplosning av 2,5 g 1,3-diacetyl-2-[(2-isopropenyl-5-metyl)-fenylJ-5-(3-metyl-2-oktyl)resorcinol i 100 ml deoksygenert ben-zen med 1,0 g tristrifenylfosfinrhodiumklorid ble hydrogenert under tre atmosfæres trykk ved romtemperatur over natten. Opp-løsningen ble konsentrert til torrhet i vakuum. Resten ble opp-lost i eter og eteropplosningen ble fort gjennom en "Florisil"-kolonne for å fjerne katalysatoren. Elueringsmidlet ble konsentrert i vakuum for å gi produktet.
EKSEMPEL 13
2-L(2-isopropyl-5-metyl)fenyl]-5-(3-metyl-2-oktyl)resorcinol
2- |_ ( 2-isopro -5yl-5-metyl) fenyl]-5- (3-metyl- 2-oktyl)resorcinol ble fremstilt ved å behandle 1,3-diacetyl-2-[(2-isopropyl-5-metyl)fenyl]-5-(3-metyl-2-oktyl)resorcinol med ammoniakk ifolge fremgangsmåten i eksempel 7, og renset ved kromatografi på en "Florisil"-kolonne (60-100 mesh) under anvendelse av gradert eter/petroleter-(30-60°) opplosningsmiddelblandinger.
Analyse beregnet for: C25H36°2: C' 81>47>hj 9>855 °t 8,68
funnet : C, 80,91; H, 9,85; 0, 8,99
EKSEMPEL 14
Mange prover er blitt foretatt under anvendelse av forbindelsene ifolge foreliggende oppfinnelse for å bestemme deres anvend-barhet og effektivitet som anti-psykotiske, analgetiske og anti-konvulsive midler. Provene som anvender forbindelsene ifolge foreliggende oppfinnelse er beskrevet nedenfor og resultatene for disse prover er angitt nedenfor i tabell I.
Prove 1
Anti- psykotisk aktivitet
(Rotte-"Desoxyn"-antagonisme)
Antipsykotisk aktivitet ("Desoxyn"-anta gonisme) ble bestemt
i motoraktivitetskamre utstyrt med fotoceller. Grupper på ni rotter ble inngitt forbindelsen oralt 1 time for proven og methamphetamin ("Desoxyn") ble derpå administrert i en mengde på 3 mg/k.g subkutant, og anbragt i kammeret. Forandringer i mo-toraktivitet ble oppfort som impulser fra fotoceller og sammen-lignes med "Desoxyn"-behandlete kontroller.
Prove 2
Analgetisk aktivitet
Ved provning med hensyn til analgetisk effekt av de foreliggende forbindelser ble eddiksyre-vridningsproven utfort slik som beskrevet av [b.A. Whittle, Brit. J. Pharmacol 22, 246 (1964)]. Grupper av Swiss-Webster-hunmus ble inngitt orale doser av forbindelsen eller kontrollbæreren. Anvendelsen av det intravenose fargestoff ble eliminert. 1 time senere ble de inngitt 0,4 ml 0,5% HOAc intraperitonealt. Antallet vridninger som inntraff i lopet av 20 minutter ble tellet idet man begynte 5 minutter etter injeksjonen av HOAc. Analgetisk aktivitet ble oppfort som prosent vridningshemning versus kontroller eller som ED^^<.>
Ved provning med hensyn til analgetisk aktivitet ved anvendelse av rottehalebevegelsesmetoden beskrevet av [f.E. D'Amour og D.
L. Smith, J Pharmcol. Exp. Ther. 72, 7 4 (1941)] ble metoden mo-difisert som folger. Grupper av Sprague-Dawley-hanrotter som veier 140-170 g prepareres med å svarte deres haler med "India"-sort. Strålevarme fokuseres på deres haler og justeres slik at den normale smerteterskel (tid i sekunder inntil en unn-vikningsreaksjon eller halebevegelse inntreffer) er innen om-rådet 8 til 10 sekunder. Dette folges av oral administrasjon av proveforbindelsen og målinger hver time av dyrenes smerteterskel. De analgetiske effekter angis i tabell I som prosent okning over den opprinnelige smerteterskel 2 timer etter dose-ring eller ED5Q .
Prove 3
Audiogen anfallsprove
(mus)
En stamme av 0'Grådy-hanmus (14 til 16 g) spesielt alet opp for mottagelighet overfor audiogene anfall ble anvendt som forsdks-dyr. Det audiogene apparat besto av en treboks som omgir en me-tallbeholder med to dorklokker festet til den ovre del. Etter administrasjon av forbindelsen ble dyrene anbragt i det audiogene kammer og klokkene aktivert i ett minutt og dyrene ble iakttatt med hensyn til krampe, [ref.: N.P. Plotnikoff og D.M. Green, J. Pharmacol. Exp. Ther., 119, 294 (1957)].
i
Claims (1)
- Analogifremgangsmåte ved fremstilling av terapeutisk aktive 2-substituerte-5-alkylresorcinol med formelen hvor Z = -C ( = CH2). CH3 eller -CH (CH3)2 og hvor betyr hydrogen eller acetyl og R2 betyr 3-metyl-2-oktyl, og X er nitrogen eller C-metyl, karakteri- sert ved at en forbindelse med formel (B) omsettes med eddiksyreanhydrid i pyridin for oppnåelse av en forbindelse med formel (A) hvor R^ = acetyl og Z = -C (=CH2)-CH3og, om ønskes, hydrogeneres den oppnådde forbindelse for fremstilling av en forbindelse med formel (A) hvor Z = -CH(CH3)2og/eller deacetyleres den oppnådde forbindelse for fremstilling av en forbindelse med formel (A) hvor R^ = H.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/632,126 US4018777A (en) | 1975-11-14 | 1975-11-14 | 2-Substituted-5-alkyl resorcinols |
Publications (3)
Publication Number | Publication Date |
---|---|
NO763881L NO763881L (no) | 1977-05-18 |
NO146060B true NO146060B (no) | 1982-04-13 |
NO146060C NO146060C (no) | 1982-08-04 |
Family
ID=24534181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO763881A NO146060C (no) | 1975-11-14 | 1976-11-12 | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-substituerte-5-alkylresorcinol |
Country Status (18)
Country | Link |
---|---|
US (1) | US4018777A (no) |
JP (1) | JPS5262254A (no) |
AU (1) | AU511431B2 (no) |
CA (1) | CA1090346A (no) |
CH (1) | CH618427A5 (no) |
DE (1) | DE2651708A1 (no) |
DK (1) | DK506776A (no) |
FI (1) | FI763241A (no) |
FR (2) | FR2361887A1 (no) |
GB (1) | GB1541858A (no) |
GR (1) | GR61763B (no) |
MX (1) | MX4120E (no) |
NL (1) | NL7612607A (no) |
NO (1) | NO146060C (no) |
PH (1) | PH12341A (no) |
PT (1) | PT65816B (no) |
SE (1) | SE428800B (no) |
ZA (1) | ZA766571B (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
US20020137802A1 (en) * | 2000-09-28 | 2002-09-26 | Travis Craig R. | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation |
US6541510B2 (en) * | 2000-09-28 | 2003-04-01 | Immugen Pharmaceuticals, Inc. | Antiviral methods and compounds |
US20030232101A1 (en) * | 2002-03-18 | 2003-12-18 | Immugen Pharmaceuticals, Inc. | Topical formulations of resorcinols and cannibinoids and methods of use |
JP2006511460A (ja) * | 2002-08-23 | 2006-04-06 | ユニバーシティ オブ コネチカット | 治療適応を持つケトカンナビノイド |
US20040087590A1 (en) * | 2002-08-23 | 2004-05-06 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
CN102712589B (zh) * | 2009-11-17 | 2015-05-13 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的芳基-吡啶衍生物 |
RU2019132968A (ru) * | 2017-05-09 | 2021-06-09 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Кристаллы пиранодипиридинового соединения |
CA3132841A1 (en) * | 2019-03-08 | 2020-09-17 | The Regents Of The University Of California | Use of 8,9-dihydrocannabidiol compounds |
WO2020186077A1 (en) * | 2019-03-12 | 2020-09-17 | 6th Wave Innovations Corp. | Molecularly imprinted polymers for extraction of cannabinoids and uses thereof |
AU2021386606A1 (en) | 2020-11-24 | 2023-06-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3901926A (en) * | 1973-04-02 | 1975-08-26 | Abbott Lab | Alkylphenyl benzopyrans |
-
1975
- 1975-11-14 US US05/632,126 patent/US4018777A/en not_active Expired - Lifetime
-
1976
- 1976-11-02 ZA ZA766571A patent/ZA766571B/xx unknown
- 1976-11-08 CA CA265,182A patent/CA1090346A/en not_active Expired
- 1976-11-09 FR FR7633756A patent/FR2361887A1/fr active Granted
- 1976-11-10 PT PT65816A patent/PT65816B/pt unknown
- 1976-11-10 DK DK506776A patent/DK506776A/da not_active Application Discontinuation
- 1976-11-10 JP JP51134255A patent/JPS5262254A/ja active Pending
- 1976-11-10 MX MX765115U patent/MX4120E/es unknown
- 1976-11-10 PH PH7619113A patent/PH12341A/en unknown
- 1976-11-11 SE SE7612620A patent/SE428800B/xx unknown
- 1976-11-11 GR GR52161A patent/GR61763B/el unknown
- 1976-11-11 FI FI763241A patent/FI763241A/fi not_active Application Discontinuation
- 1976-11-12 NL NL7612607A patent/NL7612607A/xx not_active Application Discontinuation
- 1976-11-12 GB GB47323/76A patent/GB1541858A/en not_active Expired
- 1976-11-12 NO NO763881A patent/NO146060C/no unknown
- 1976-11-12 DE DE19762651708 patent/DE2651708A1/de active Pending
- 1976-11-12 CH CH1431076A patent/CH618427A5/fr not_active IP Right Cessation
-
1977
- 1977-01-07 AU AU21148/77A patent/AU511431B2/en not_active Expired
- 1977-05-05 FR FR7713746A patent/FR2397385A1/fr active Granted
Also Published As
Publication number | Publication date |
---|---|
GR61763B (en) | 1979-01-09 |
SE7612620L (sv) | 1977-05-15 |
NL7612607A (nl) | 1977-05-17 |
GB1541858A (en) | 1979-03-07 |
FR2397385A1 (fr) | 1979-02-09 |
FR2397385B1 (no) | 1980-04-25 |
PT65816A (en) | 1976-12-01 |
FR2361887A1 (fr) | 1978-03-17 |
PH12341A (en) | 1979-01-16 |
PT65816B (en) | 1978-05-12 |
CH618427A5 (no) | 1980-07-31 |
DE2651708A1 (de) | 1977-05-18 |
SE428800B (sv) | 1983-07-25 |
NO763881L (no) | 1977-05-18 |
DK506776A (da) | 1977-05-15 |
AU2114877A (en) | 1978-07-13 |
NO146060C (no) | 1982-08-04 |
AU511431B2 (en) | 1980-08-21 |
FR2361887B1 (no) | 1979-03-09 |
ZA766571B (en) | 1977-10-26 |
JPS5262254A (en) | 1977-05-23 |
US4018777A (en) | 1977-04-19 |
MX4120E (es) | 1981-12-15 |
FI763241A (no) | 1977-05-15 |
CA1090346A (en) | 1980-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO146060B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-substituerte-5-alkylresorcinol | |
NO136492B (no) | ||
Bunnett et al. | Studies of Ring Closure via Aryne Intermediates1 | |
Welstead Jr et al. | Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid | |
Popp et al. | Reissert compound studies. XVIII. Analogs derived from chloroformates | |
Walker | Hypotensive methoxyisoquinolines | |
NO144529B (no) | Fremgangsmaate ved fremstilling av benzo-(a)-kinolizinderivater | |
Neumeyer et al. | Isoquinolines. 3. 3-Aminoisoquinoline derivatives with central nervous system depessant activity | |
WO1981003173A1 (en) | Thieno-tricyclic compounds,method for the preparation thereof,utilization of such compounds and drugs containing them | |
Redda et al. | Syntheses of N-substituted 2 (3, 4)-pyridylcarboxylic acid hydrazides with analgesic and antiinflammatory activity | |
DD204699A5 (de) | Verfahren zur herstellung von benzofuranonen | |
DE102006031176A1 (de) | Substituierte Benzoxepino-isoxazole und ihre Verwendung | |
CA1078395A (en) | Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation | |
US4420476A (en) | Benzofuro[3,2-c]pyrazol-3-amine derivatives | |
Harley-Mason et al. | Hydroxytryptamines. Part II. A new synthesis of physostigmine | |
Nesnow et al. | Reaction of 6-hydroxy-2 (1H)-pyridone with diazomethane. Isolation of a novel product | |
Huckle et al. | 4-Amino-2, 3, 4, 5-tetrahydro-1-benzoxepin-5-ols, 4-amino-2, 3, 4, 5-tetrahydro-1-benzothiepin-5-ols, and related compounds | |
EP0025501B1 (de) | Neue N-Aminoalkylindol-Derivate und ihre Salze; Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
Grol et al. | Synthesis and neuroleptic activity of isomeric thieno [1, 4] benzothiazines | |
CH637958A5 (de) | Verfahren zur herstellung neuer pyridobenzodiazepinone und ihrer salze. | |
Coates et al. | 2, 4-Diarylthiete 1, 1-dioxides. Synthesis, thermolysis studies, and addition reactions | |
US3631069A (en) | Substituted phenethyl alcohols and their esters | |
Moffett et al. | Antiulcer agents. 2. Pyridyl oxime ethers | |
DD208798A5 (de) | Verfahren zur herstellung von phenol-derivate | |
Eisch et al. | Nonpyridinoid aza-aromatic systems. II. Reactions of the anions of benzo [b][1] pyrindine and its 1, 2-dihydro derivative |